Apitope - Articles and news items

Apitope’s Phase II multiple sclerosis trial a success

Industry news / 22 February 2017 / Niamh Marriott, Digital Editor

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase IIa, open-label, one arm study evaluated the effects of ATX-MS-1467 in 19 patients with […]

Apitope regains global rights to its multiple sclerosis treatment from Merck

Industry news / 18 October 2016 / Niamh Louise Marriott, Digital Content Producer

In 2009, Apitope granted exclusive worldwide rights to Merck to develop and commercialise ATX-MS-1467 but now have successfully regained…

Enrolment completes for Phase IIa trial of ATX-MS-1467

Industry news / 6 August 2015 / Victoria White

Apitope today announced that its partner, Merck Serono, has completed patient enrolment for the Phase IIa study of ATX-MS-1467 (also known as M2736)…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...